Kalra Sanjay, Aamir A H, Raza Abbas, Das A K, Azad Khan A K, Shrestha Dina, Qureshi Md Faisal, Pathan Md Faruque, Jawad Fatema, Bhattarai Jyoti, Tandon Nikhil, Somasundaram Noel, Katulanda Prasad, Sahay Rakesh, Dhungel Sanjib, Bajaj Sarita, Chowdhury Subhankar, Ghosh Sujoy, Madhu S V, Ahmed Tofail, Bulughapitiya Uditha
Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, Haryana, India.
Department of Endocrinology, Post Graduate Medical Institute Hayatabad Medical Complex, Peshawar, Pakistan.
Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96. doi: 10.4103/2230-8210.163171.
Since their introduction in clinical practice in the 1950's, Sulfonylureas (SUs) have remained the main-stay of pharmacotherapy in the management of type 2 diabetes. Despite their well-established benefits, their place in therapy is inappropriately being overshadowed by newer therapies. Many of the clinical issues associated with the use of SUs are agent-specific, and do not pertain to the class as such. Modern SUs (glimepiride, gliclazide MR) are backed by a large body of evidence, experience, and most importantly, outcome data, which supports their role in managing patients with diabetes. Person-centred care, i.e., careful choice of SU, appropriate dosage, timing of administration, and adequate patient counseling, will ensure that deserving patients are not deprived of the advantages of this well-established class of anti-diabetic agents. Considering their efficacy, safety, pleiotropic benefits, and low cost of therapy, SUs should be considered as recommended therapy for the treatment of diabetes in South Asia. This initiative by SAFES aims to encourage rational, safe and smart prescription of SUs, and includes appropriate medication counseling.
自20世纪50年代引入临床实践以来，磺脲类药物（SUs）一直是2型糖尿病药物治疗的主要手段。尽管其益处已得到充分证实，但在治疗中的地位正被更新的疗法不适当地掩盖。许多与使用SUs相关的临床问题是特定药物的，并不适用于整个类别。现代SUs（格列美脲、缓释格列齐特）有大量证据、经验支持，最重要的是有结局数据支持它们在糖尿病患者管理中的作用。以患者为中心的护理，即谨慎选择SU、合适的剂量、给药时间以及充分的患者咨询，将确保有需求的患者不会被剥夺这类成熟的抗糖尿病药物的优势。考虑到其疗效、安全性、多效性益处以及治疗成本低，SUs应被视为南亚糖尿病治疗的推荐疗法。SAFES的这项倡议旨在鼓励合理、安全和明智地使用SUs处方，并包括适当的用药咨询。
